{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:50:00Z","timestamp":1771501800201,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.clgc.2016.03.018","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T13:17:29Z","timestamp":1458825449000},"page":"e559-e568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Per","family":"Kongsted","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.03.018_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2016.03.018_bib2","doi-asserted-by":"crossref","first-page":"vi106","DOI":"10.1093\/annonc\/mdt208","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.03.018_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.03.018_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.03.018_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clgc.2016.03.018_bib8","article-title":"Docetaxel and\/or zoledronic acid for hormone-na\u00efve prostate cancer: first overall survival results from STAMPEDE (NCT00268476)","volume":"33","author":"James","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.03.018_bib10","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.03.018_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2310\/JIM.0b013e3181cf9002","article-title":"Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy","volume":"58","author":"Chao","year":"2010","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.clgc.2016.03.018_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrd3501","article-title":"Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response","volume":"10","author":"Eichler","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clgc.2016.03.018_bib13","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.eururo.2008.07.078","article-title":"Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer","volume":"55","author":"Italiano","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.03.018_bib15","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgo.2013.12.001","article-title":"Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial","volume":"5","author":"Horgan","year":"2014","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib17","doi-asserted-by":"crossref","first-page":"494.e15","DOI":"10.1016\/j.urolonc.2015.06.022","article-title":"Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?","volume":"33","author":"Kongsted","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","article-title":"Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review","volume":"29","author":"Lee","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2010-0354","article-title":"Chemotherapy-related hospitalization among community cancer center patients","volume":"16","author":"Hassett","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2016.03.018_bib21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.1998.16.4.1582","article-title":"Comorbidity and functional status are independent in older cancer patients","volume":"16","author":"Extermann","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1054\/blre.2002.0193","article-title":"Pathogenesis and treatment of anaemia of chronic disease","volume":"16","author":"Weiss","year":"2002","journal-title":"Blood Rev"},{"key":"10.1016\/j.clgc.2016.03.018_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2005.03.082","article-title":"Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly","volume":"23","author":"ten Tije","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomized trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomized, double blind phase 3 trial","volume":"14","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jgo.2014.09.183","article-title":"Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer","volume":"6","author":"Leibowitz-Amit","year":"2015","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clgc.2016.03.018_bib27","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.ejca.2013.06.008","article-title":"Analysis of docetaxel therapy in elderly (\u226570 years) castration resistant prostate cancer patients\u00a0enrolled in the Netherlands Prostate Study","volume":"49","author":"Gerritse","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.03.018_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.03.018_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316300726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316300726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:21Z","timestamp":1761564381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316300726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1558767316300726"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.03.018","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}